keyword
MENU ▼
Read by QxMD icon Read
search

Ozurdex

keyword
https://www.readbyqxmd.com/read/29207977/acute-zonal-occult-outer-retinopathy-azoor-a-case-report-of-vision-improvement-after-intravitreal-injection-of-ozurdex
#1
Yi Chun Kuo, Nancy Chen, Rong Kung Tsai
BACKGROUND: AZOOR was first described by Gass in 1993 as a syndrome with rapid loss of one or more extensive zones of the outer retinal segments. It is characterized by photopsia, minimal funduscopic changes, and electroretinographic abnormalities. The efficacy of systemic steroids in treating AZOOR has been previously described and advocated by the concept of autoimmune retinopathy. However, the use of intravitreal of sustained-released steroid had not been mentioned to date. CASE PRESENTATION: A 34-year-old man had sudden onset of central scotoma and photopsia in the left eye...
December 6, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/29192395/intracrystalline-ozurdex%C3%A2-therapeutic-effect-maintained-for-18%C3%A2-months
#2
Rodrigo Clemente-Tomás, Delia Hernández-Pérez, Paulina Neira-Ibáñez, Francisco Farías-Rozas, Raúl Torrecillas-Picazo, Vanesa Osorio-Alayo, Antonio M Duch-Samper
INTRODUCTION: Ozurdex® is a sterile, sustained-release implant of dexamethasone. The device dissolves within the vitreous body and releases dexamethasone. Here we present a clinical case that demonstrates the sustained therapeutic efficacy of Ozurdex® when accidentally injected into the crystalline lens. METHODS: Case report. RESULTS: Sixty-three-year-old male in which we decided to prescribe the intravitreal injection of a dexamethasone implant (Ozurdex®) in the left eye because of macular oedema after branch retinal vein occlusion...
November 30, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/29183563/a-systematic-review-and-economic-evaluation-of-adalimumab-and-dexamethasone-for-treating-non-infectious-intermediate-uveitis-posterior-uveitis-or-panuveitis-in-adults
#3
Hazel Squires, Edith Poku, Inigo Bermejo, Katy Cooper, John Stevens, Jean Hamilton, Ruth Wong, Alastair Denniston, Ian Pearce, Fahd Quhill
BACKGROUND: Non-infectious intermediate uveitis, posterior uveitis and panuveitis are a heterogeneous group of inflammatory eye disorders. Management includes local and systemic corticosteroids, immunosuppressants and biological drugs. OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of subcutaneous adalimumab (Humira®; AbbVie Ltd, Maidenhead, UK) and a dexamethasone intravitreal implant (Ozurdex®; Allergan Ltd, Marlow, UK) in adults with non-infectious intermediate uveitis, posterior uveitis or panuveitis...
November 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/29155696/safety-of-consecutive-same-day-bilateral-intravitreal-dexamethasone-implant-ozurdex
#4
Kapil G Kapoor, James B Colchao
PURPOSE: The objective of this study was to evaluate patient safety and tolerance of consecutive bilateral intravitreal dexamethasone (Ozurdex) injections during a single visit for the treatment of cystoid macular edema secondary to retinal vein occlusion, diabetic macular edema, or noninfectious posterior uveitis. METHODS: This was a retrospective single-center institutional review board-approved study from March 1, 2013, through August 1, 2016. All patients had a complete ophthalmologic examination and optical coherence tomography imaging...
November 16, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/29119239/safety-and-efficacy-of-dexamethasone-intravitreal-implant-for-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-chinese-patients-randomized-sham-controlled-multicenter-study
#5
Xiaoxin Li, Ningli Wang, Xiaoling Liang, Gezhi Xu, Xiao-Yan Li, Jenny Jiao, Jean Lou, Yehia Hashad
PURPOSE: The purpose of this study was to evaluate the safety and efficacy of dexamethasone intravitreal implant 0.7 mg (DEX) for treatment of macular edema associated with retinal vein occlusion (RVO). METHODS: This study was a six-month, randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial with a 2-month open-label study extension. Patients with branch or central RVO received DEX (n = 129) or sham procedure (n = 130) in the study eye at baseline; all patients who met re-treatment criteria received DEX at month 6...
November 8, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29109896/outcomes-of-intravitreal-dexamethasone-implant-in-the-treatment-of-recalcitrant-diabetic-macular-edema
#6
Dorukcan Akıncıoğlu, Murat Küçükevcilioğlu, Ali Hakan Durukan, Seçkin Aykaş, Önder Ayyıldız, Fazıl Cüneyt Erdurman
Objectives: To investigate the efficacy and safety of intravitreal dexamethasone (OZURDEX®) implantation in patients with recalcitrant diabetic macular edema. Materials and Methods: This is a retrospective non-randomized study of patients who underwent intravitreal dexamethasone implantation for recalcitrant diabetic macular edema. Main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and incidence of ocular side effects...
October 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/29108392/cauterization-of-ozurdex-wound-for-the-prevention-of-scleral-leakage-in-vitrectomized-eyes
#7
Claudio Furino, Nicola Recchimurzo, Francesco Boscia, Giovanni Alessio
PURPOSE: To study if cauterization of the scleroconjuctival wound secondary to intravitreal dexamethasone implant in vitrectomized eyes is effective to avoid scleral leakage and hypotony. METHODS: A total of 35 vitrectomized eyes of 35 consecutive patients with macular edema who underwent a single intravitreal dexamethasone implant injection in the operating room at the Eye Clinic of the University of Bari, Italy, from 2013 to 2017 were retrospectively reviewed...
October 31, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29099501/efficacy-and-timing-of-adjunctive-therapy-in-the-anti-vegf-treatment-regimen-for-macular-oedema-in-retinal-vein-occlusion-12-month-real-world-result
#8
P L Lip, P Cikatricis, A Sarmad, E M Damato, R Chavan, A Mitra, S Elsherbiny, Y Yang, B Mushtaq
PurposeVarious combination treatment regimens have been tried to improve the short-term efficacy of intravitreal monotherapy for the treatment of macular oedema (MO) secondary to retinal vein occlusion (RVO). Our study introduces the RandOL protocol (Ranibizumab and Ozurdex with Laser photocoagulation) of initial anti-VEGF therapy, controlling recurrent non-ischaemic MO with an intravitreal steroid and applying laser therapy to non-perfused retina. We describe our 12-month follow-up experience on timing for adjunctive therapy and real-world effectiveness and safety data...
November 3, 2017: Eye
https://www.readbyqxmd.com/read/29098101/a-new-side-effect-of-intravitreal-dexamethasone-implant-ozurdex%C3%A2
#9
Erdem Eris, Gurkan Erdogan, Irfan Perente, Gokhan Demir, Burcin Kepez Yildiz, Ebru Demet Aygit
Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion. By reporting this case we aimed to report a new side effect of 0.7 mg intravitreal dexamethasone implant that has not been reported in the literature before.
2017: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/29062594/new-drugs-and-new-posterior-delivery-methods-in-cme
#10
João Rafael de Oliveira Dias, Renata Portella Nunes, Raquel Goldhardt
PURPOSE: To discuss the characteristics, indications and adverse events (AEs) of sustained-release corticosteroid devices for the treatment of cystoid macular edema (CME). RECENT FINDINGS: Ozurdex® is approved for the treatment of diabetic macular edema (DME), retinal vein occlusion related-CME and noninfectious posterior uveitis (NIPU). It releases dexamethasone over a maximum period of 6 months making repeated intravitreal injections necessary for recurrent CME...
June 2017: Current Ophthalmology Reports
https://www.readbyqxmd.com/read/29020496/clinical-outcomes-of-adjunctive-sustained-release-intravitreal-dexamethasone-implants-in-tuberculosis-associated-multifocal-serpigenoid-choroiditis
#11
Lubhani Jain, Krushna Gopal Panda, Soumyava Basu
PURPOSE: To analyze the safety and efficacy of sustained-release intravitreal dexamethasone implant (Ozurdex) in management of TB-associated multifocal serpiginoid choroiditis (MSC). METHODS: Retrospective review of TB-associated MSC patients, treated with anti-TB therapy (ATT) and adjunctive intravitreal Ozurdex. RESULTS: Nine eyes of six patients were included. Four patients required Ozurdex implant for progressive or new lesions following ATT and two for additional systemic contraindications to corticosteroids - hyperglycemia and uncontrolled hypertension, respectively...
October 11, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28973374/effects-of-intravitreal-dexamethasone-implants-on-retinal-oxygen-saturation-vessel-diameter-and-retrobulbar-blood-flow-velocity-in-me-secondary-to-rvo
#12
Katharina Eibenberger, Leopold Schmetterer, Sandra Rezar-Dreindl, Piotr Wozniak, Reinhard Told, Georgios Mylonas, Christoph Krall, Ursula Schmidt-Erfurth, Stefan Sacu
Purpose: To investigate the effects of intravitreal 0.7 mg dexamethasone implants (Ozurdex) on arterial and venous oxygen saturation, retinal vessel diameter, and retrobulbar blood flow velocity in patients with macular edema (ME) due to retinal vein occlusion (RVO). Methods: This prospective, nonrandomized clinical trial included 40 eyes of 40 patients with ME due to RVO. Measurements of arterial and venous oxygen saturation and retinal vessel diameters were performed using the Dynamic Vessel Analyzer...
October 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28949790/the-effect-of-age-and-initial-central-retinal-thickness-on-earlier-need-of-repeat-ozurdex-treatment-for-macular-edema-due-to-retinal-vein-occlusion-a-retrospective-case-series
#13
Chun-Ju Lin, Huan-Sheng Chen, Cheng-Wen Su, Peng-Tai Tien, Jane-Ming Lin, Wen-Lu Chen, Chung-Yuan Kuo, Chun-Ting Lai, Yi-Yu Tsai
PURPOSE: To evaluate the effects of dexamethasone intravitreal implant (Ozurdex) and identify risk factors for repeated treatment in patients with macula edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). METHODS: Patients followed up for at least 6 months were enrolled from 2013 to 2016. Dexamethasone intravitreal implant was given as the baseline treatment. For evaluation of dexamethasone intravitreal implant effects and complications, the demographics, medical history, best-corrected visual acuity (BCVA), intraocular pressure, and central retinal thickness (CRT) were recorded...
September 26, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28918546/systemic-effects-of-repeated-intraocular-dexamethasone-intravitreal-implant-in-diabetic-patients-a-retrospective-study
#14
Alicia Valverde-Megías, Pilar Cifuentes-Canorea, Jorge Ruiz-Medrano, Pablo Peña-García, Alicia Megías-Fresno, Juan Donate-López, Julián García-Feijoo
INTRODUCTION: The objective of this study is to evaluate the influence of repeated intraocular dexamethasone implant (Ozurdex) injections on metabolic control in type 2 diabetic patients. METHODS: Retrospective study of 165 type 2 diabetic patients starting Ozurdex treatment who received no less than three consecutive injections. Glycated hemoglobin (HbA1c), serum creatinine, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides (TGs) were evaluated during 15 months of follow-up after Ozurdex treatment onset...
October 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28884024/combined-phacoemulsification-and-intravitreal-dexamethasone-implant-ozurdex%C3%A2-in-diabetic-patients-with-coexisting-cataract-and-diabetic-macular-edema
#15
Claudio Furino, Francesco Boscia, Alfredo Niro, Ermete Giancipoli, Maria Oliva Grassi, Giuseppe D'amico Ricci, Francesco Blasetti, Michele Reibaldi, Giovanni Alessio
PURPOSE: To investigate the effectiveness and safety of combined phacoemulsification and dexamethasone intravitreal implant in patients with cataract and diabetic macular edema. METHODS: In this two-center, retrospective, single-group study, the charts of 16 consecutive patients who underwent combined phacoemulsification and intravitreal dexamethasone implant were retrospectively reviewed. These 16 patients, 7 men and 9 women, were observed at least 3 months of follow-up...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28839510/combined-intravitreal-dexamethasone-implant-and-micropulse-yellow-laser-for-treatment-of-anti-vegf-resistant-diabetic-macular-edema
#16
Ahmed Hosni Abd Elhamid
PURPOSE: To report the efficacy and safety of combined intravitreal dexamethasone implant and micropulse laser for anti-VEGF resistant diabetic macular edema. PATIENTS AND METHODS: Prospective, non-controlled study that was conducted for twenty eyes with center-involved diabetic macular edema not responding to anti-VEGF therapy. Ozurdex intravitreal implant was injected to all eyes with subsequent micropulse yellow laser one month after the injection. All eyes were followed up after one, three, four, six, nine and twelve months...
2017: Open Ophthalmology Journal
https://www.readbyqxmd.com/read/28757698/the-nomadic-ozurdex-%C3%A2-anterior-migration-of-the-dexamethasone-implant-and-back
#17
Priya Srinivasan, Chaitra Jayadev, Rohit Shetty
Dexamethasone intravitreal implantation has been used in various retinal and uveal pathologies. Common complications include cataract formation and raised intraocular pressure. Although uncommon, migration of the implant has also been well reported. We describe a case with migration of the implant into the anterior chamber in a patient with a scleral-fixated intraocular lens, which was managed noninvasively by pupillary dilatation and positioning of the patient.
May 2017: Oman Journal of Ophthalmology
https://www.readbyqxmd.com/read/28757695/iatrogenic-subretinal-injection-of-ozurdex-%C3%A2-implant-and-its-effect-on-macular-edema
#18
Smita Shriram Karandikar, George J Manayath, Veerappan Saravanan, Siddharth Narendran, Venkatapathy Narendran
PURPOSE: The purpose of this study was to report a rare case of subretinal lodgement of Ozurdex(®) implant (Allergan Inc., Irvine, CA, USA) and its effect on macular edema in a case of central retinal vein occlusion (RVO). METHODS: A rare complication of subretinal lodgement of Ozurdex(®) implant without retinal perforation was encountered in a case of RVO with intractable macular edema. As associated retinal perforation was not noted, no intervention was done...
May 2017: Oman Journal of Ophthalmology
https://www.readbyqxmd.com/read/28724830/drug-resistant-coagulase-negative-staphylococcal-endophthalmitis-following-dexamethasone-intravitreal-implant
#19
Prabhushanker Mahalingam, Tasneem Tameem Topiwalla, Geetha Ganesan
A 60-year-old female came to our hospital with defective vision due to persistent diabetic macular edema and was treated with intravitreal ozurdex implant in the right eye. Three days later, the patient presented with diminution of vision, ocular pain, congestion, and hypopyon with no fundus view. B-scan ultrasonography showed vitritis, and diagnosis of endophthalmitis was made. Subsequently, 25-gauge pars plana vitrectomy was performed along with intravitreal vancomycin and amikacin and removal of implant...
July 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28691953/ozurdex%C3%A2-dexamethasone-intravitreal-implant-0-7-mg-for-use-in-noninfectious-posterior-segment-uveitis-a-case-based-discussion
#20
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Retina
keyword
keyword
33543
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"